Sybleu (OTCPK:SYBE) - Stock Price, News & Analysis

SYBE Stock Overview

SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. More details

SYBE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($584K)

Shares are highly illiquid

Earnings have declined by 25.4% per year over past 5 years

Negative shareholders equity

+ 2 more risks

Sybleu Inc. Competitors

Resonate Blends

OTCPK:KOAN

US$502.0k

Kaya Holdings

OTCPK:KAYS

US$709.5k

SciSparc

NasdaqCM:SPRC

US$1.0m

AmeriCann

OTCPK:ACAN

US$523.8k

Price History & Performance

Summary of all time highs, changes and price drops for Sybleu
Historical stock prices
Current Share Price	US$0.055
52 Week High	US$0.15
52 Week Low	US$0.011
Beta	0
11 Month Change	0%
3 Month Change	8.91%
1 Year Change	10.44%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.00%

Recent updates

Shareholder Returns

	SYBE	US Pharmaceuticals	US Market
7D	0%	1.6%	2.2%
1Y	10.4%	10.0%	31.7%

Return vs Industry: SYBE underperformed the US Pharmaceuticals industry which returned 19.7% over the past year.

Return vs Market: SYBE underperformed the US Market which returned 33.7% over the past year.

Price Volatility

Is SYBE's price volatile compared to industry and market?
SYBE volatility
SYBE Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SYBE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SYBE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	n/a	Joseph Vaini	n/a

SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials.

Sybleu Inc. Fundamentals Summary

How do Sybleu's earnings and revenue compare to its market cap?
SYBE fundamental statistics
Market cap	US$583.74k
Earnings (TTM)	-US$307.89k
Revenue (TTM)	US$11.70k

49.9x

P/S Ratio

-1.9x

P/E Ratio

Is SYBE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYBE income statement (TTM)
Revenue	US$11.70k
Cost of Revenue	US$0
Gross Profit	US$11.70k
Other Expenses	US$319.58k
Earnings	-US$307.89k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.029
Gross Margin	100.00%
Net Profit Margin	-2,632.19%
Debt/Equity Ratio	-125.3%

How did SYBE perform over the long term?

See historical performance and comparison

Sybleu OTCPK:SYBE Stock Report